SYNEDGEN, INC.

SUPPLEMENTAL FUNDING FOR CLIN 0001; UPDATE THE POP FOR CLINS 0001 - 0007; UPDATE THE SOW AND MILESTONE TABLE ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY A

ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE TO IONIZING RADIATION, SPECIFICALLY GASTROINTESTINAL (GI) INJURY (GI-AR

SBIR PHASE III PROPOSAL NO. JW230017 TITLED, "OPTIMIZED, FIELD-STABLE GLYCOPOLYMER-MIMICKING POLYSACCHARIDE TO PREVENT MORBIDITY AND MORTALITY IN EXPOSURE TO IONIZING RADIATION OR NUCLEAR INJURY"

AWARD OF SYNEDGEN'S DHA SBIR PHASE III FOLLOW-ON MEDICAL R&D CONTRACT FOR "DEVELOPMENT OF TECHNOLOGIES THAT CONTROL SCAR FORMATION AFTER BURN INJURIES"